Evidence map›Paper›PMID 33882086›Full record

ArticlePloS one2021

Optimal allocations for two treatment comparisons within the proportional odds cumulative logits model.

Mirjam Moerbeek

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05684367 (Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05684367 narecruitingnot on this mapstarted 2023, after this paper: background citation

Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors

TypeinterventionalSponsorUniversity of FloridaRan2023 to 2026Enrolled24ConditionsFatigue, Breast Cancer, Cancer, Therapy-RelatedArmsCenter-Based Walking Exercise, Home-Based Walking Exercise
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mirjam MoerbeekDepartment of Methodology and Statistics, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-5537-1237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper studies optimal treatment allocations for two treatment comparisons when the outcome is ordinal and analyzed by a proportional odds cumulative logits model. The variance of the treatment effect estimator is used as optimality criterion. The optimal design is sought so that this variance is minimal for a given total sample size or a given budget, meaning that the power for the test on treatment effect is maximal, or it is sought so that a required power level is achieved at a minimal total sample size or budget. Results are presented for three, five and seven ordered response categories, three treatment effect sizes and a skewed, bell-shaped or polarized distribution of the response probabilities. The optimal proportion subjects in the intervention condition decreases with the number of response categories and the costs for the intervention relative to those for the control. The relation between the optimal proportion and effect size depends on the distribution of the response probabilities. The widely used balanced design is not always the most efficient; its efficiency as compared to the optimal design decreases with increasing cost ratio. The optimal design is highly robust to misspecification of the response probabilities and treatment effect size. The optimal design methodology is illustrated using two pharmaceutical examples. A Shiny app is available to find the optimal treatment allocation, to evaluate the efficiency of the balanced design and to study the relation between budget or sample size and power.

Indexed as

Logistic ModelsData Interpretation, StatisticalHumansModels, StatisticalProbabilitySample Size

Identifiers

PMID33882086
PMCPMC8059828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.